Peter Michael Moyle
Cited by
Cited by
Modern subunit vaccines: development, components, and research opportunities
PM Moyle, I Toth
ChemMedChem 8 (3), 360-376, 2013
Self-adjuvanting lipopeptide vaccines
PM Moyle, I Toth
Current medicinal chemistry 15 (5), 506-516, 2008
Mucosal immunisation: adjuvants and delivery systems
PM Moyle, RP McGeary, JT Blanchfield, I Toth
Current drug delivery 1 (4), 385-396, 2004
Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
ABM Abdel-Aal, MR Batzloff, Y Fujita, N Barozzi, A Faria, P Simerska, ...
Journal of medicinal chemistry 51 (1), 167-172, 2008
Method for the synthesis of mono-ADP-ribose conjugated peptides
PM Moyle, TW Muir
Journal of the American Chemical Society 132 (45), 15878-15880, 2010
Modern lipid‐, carbohydrate‐, and peptide‐based delivery systems for peptide, vaccine, and gene products
P Simerska, PM Moyle, I Toth
Medicinal research reviews 31 (4), 520-547, 2011
Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines
PM Moyle, C Olive, MF Ho, M Pandey, J Dyer, A Suhrbier, Y Fujita, I Toth
Journal of medicinal chemistry 50 (19), 4721-4727, 2007
Oral vaccine delivery-new strategies and technologies
P Simerska, PM Moyle, C Olive, I Toth
Current drug delivery 6 (4), 347-358, 2009
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines
PM Moyle
Biotechnology advances 35 (3), 375-389, 2017
Polymer–peptide hybrids as a highly immunogenic single-dose nanovaccine
AAH Ahmad Fuaad, Z Jia, M Zaman, J Hartas, ZM Ziora, IC Lin, PM Moyle, ...
Nanomedicine 9 (1), 35-43, 2014
Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation
PM Moyle, C Olive, MF Ho, MF Good, I Toth
Journal of medicinal chemistry 49 (21), 6364-6370, 2006
Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines
P Simerska, ABM Abdel-Aal, Y Fujita, PM Moyle, RP McGeary, ...
Journal of medicinal chemistry 51 (5), 1447-1452, 2008
Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity
M Zaman, S Chandrudu, AK Giddam, J Reiman, M Skwarczynski, ...
Nanomedicine 9 (17), 2613-2624, 2014
Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
PM Moyle, W Dai, Y Zhang, MR Batzloff, MF Good, I Toth
Bioconjugate chemistry 25 (5), 965-978, 2014
Method for the synthesis of highly pure vaccines using the lipid core peptide system
PM Moyle, C Olive, MF Good, I Toth
Journal of peptide science: an official publication of the European Peptide …, 2006
Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation
PM Moyle, C Olive, MF Ho, M Burgess, L Karpati, MF Good, I Toth
The Journal of organic chemistry 71 (18), 6846-6850, 2006
Endosome escape strategies for improving the efficacy of oligonucleotide delivery systems
Y Wan, PM Moyle, I Toth
Current medicinal chemistry 22 (29), 3326-3346, 2015
An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system
PM Moyle, J Hartas, A Henningham, MR Batzloff, MF Good, I Toth
Nanomedicine: Nanotechnology, Biology and Medicine 9 (7), 935-944, 2013
The contribution of non-human primate models to the development of human vaccines
T Rivera-Hernandez, DG Carnathan, PM Moyle, I Toth, NP West, ...
Discovery medicine 18 (101), 313, 2014
Glucagon‐like peptide‐1 (GLP‐1)‐based therapeutics: current status and future opportunities beyond type 2 diabetes
JY Cheang, PM Moyle
ChemMedChem 13 (7), 662-671, 2018
The system can't perform the operation now. Try again later.
Articles 1–20